PMC:7195088 / 15454-15816 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"655","span":{"begin":250,"end":258},"obj":"Species"},{"id":"735","span":{"begin":204,"end":223},"obj":"Chemical"},{"id":"736","span":{"begin":228,"end":246},"obj":"Chemical"},{"id":"908","span":{"begin":269,"end":277},"obj":"Disease"}],"attributes":[{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"Tax:9606"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"MESH:C558899"},{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"MESH:D006886"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":269,"end":277},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T53","span":{"begin":3,"end":4},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T54","span":{"begin":176,"end":178},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T55","span":{"begin":184,"end":186},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T56","span":{"begin":284,"end":289},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T57","span":{"begin":339,"end":344},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T58","span":{"begin":357,"end":361},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T87","span":{"begin":204,"end":223},"obj":"Chemical"},{"id":"T88","span":{"begin":204,"end":213},"obj":"Chemical"},{"id":"T89","span":{"begin":214,"end":223},"obj":"Chemical"},{"id":"T90","span":{"begin":228,"end":246},"obj":"Chemical"},{"id":"T91","span":{"begin":284,"end":289},"obj":"Chemical"}],"attributes":[{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}

{"project":"LitCovid-sentences","denotations":[{"id":"T96","span":{"begin":106,"end":278},"obj":"Sentence"},{"id":"T97","span":{"begin":279,"end":320},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}

{"project":"2_test","denotations":[{"id":"32360444-32187464-22369752","span":{"begin":184,"end":186},"obj":"32187464"}],"text":"to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22] • Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5,"}